FerlayJSoerjomataramIDikshitRet al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer2015; 136: E359–E386.
2.
Australia Institute of Health and Welfare2017. Australian Cancer Incidence and Mortality (ACIM) books: Prostate cancer. Canberra: AIHW, www.aihw.gov.au/acim-books (accessed 10 January 2018).
3.
DelongchampsNBPeyromaureMSchullAet al. Prebiopsy magnetic resonance imaging and prostate cancer detection: Comparison of random and targeted biopsies. J Urol2013; 189: 493–499.
4.
LecornetEAhmedHUHuYet al. The accuracy of different biopsy strategies for the detection of clinically important prostate cancer: A computer simulation. J Urol2012; 188: 974–980.
5.
SmithDPKingMTEggerSet al. Quality of life three years after diagnosis of localised prostate cancer: Population based cohort study. BMJ2009; 339: b4817.
6.
ChiangINChangSJPuYSet al. Major complications and associated risk factors of transrectal ultrasound guided prostate needle biopsy: A retrospective study of 1875 cases in Taiwan. J Formos Med Assoc2007; 106: 929–934.
7.
WysockJSMendhirattaNZattoniFet al. Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12-core biopsy results. BJU Int2016; 118: 515–520.
8.
PokornyMRde RooijMDuncanEet al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol2014; 66: 22–29.
9.
GordonLGJamesRTuffahaHWet al. Cost-effectiveness analysis of multiparametric MRI with increased active surveillance for low-risk prostate cancer in Australia. J Magn Reson Imaging2017; 45: 1304–1315.
10.
SimpkinAJTillingKMartinRMet al. Systematic review and meta-analysis of factors determining change to radical treatment in active surveillance for localized prostate cancer. Eur Urol2015; 67: 993–1105.
11.
BratanFNiafEMelodelimaCet al. Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: A prospective study. Eur Radiol2013; 23: 2019–2029.
12.
MoldovanPCVan den BroeckTSylvesterRet al. What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Eur Urol2017; 72: 250–266.
13.
RothHMillarJLChengACet al. The state of TRUS biopsy sepsis: Readmissions to Victorian hospitals with TRUS biopsy-related infection over 5 years. BJU Int2015; 116: 49–53.
